GlassScriptPhysician profile
Michail Vitellas
NPI 1023252293
$5,118.27
in general payments reported to CMS, 2019-2025
22 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,232 · 2020: $542 · 2021: $385 · 2022: $269 · 2023: $296 · 2024: $766 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,496.00 | 2019-2025 | Mitraclip, Triclip, Navitor |
| Novartis Pharmaceuticals Corporation | $599.81 | 2019-2025 | |
| Edwards Lifesciences Corporation | $548.72 | 2019-2024 | |
| Abiomed | $316.68 | 2020-2025 | |
| Medtronic Vascular, INC. | $257.34 | 2019 | |
| Amgen INC. | $118.54 | 2019-2023 | Repatha |
| Pfizer INC. | $113.53 | 2019-2025 | |
| Philips North America LLC | $111.83 | 2019 | |
| Recor Medical INC | $107.47 | 2024 | Paradise Renal Denervation System |
| Janssen Pharmaceuticals, INC | $89.63 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $78.28 | 2021-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.87 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $45.24 | 2024 | |
| Boston Scientific Corporation | $42.45 | 2024-2025 | Watchman, Bodyguardian |
| Haemonetics Corporation | $24.06 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $22.62 | 2021 | |
| Inspire Medical Systems, INC. | $18.74 | 2025 | Inspire |
| Nuwellis, INC. | $17.93 | 2023 | Aquadex Smartflow Console |
| Alexion Pharmaceuticals, INC. | $14.90 | 2022 | |
| Gilead Sciences, INC. | $13.75 | 2019 | |
| Chiesi USA, INC. | $13.29 | 2020 | |
| Shockwave Medical, INC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michail Vitellas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.